GlassScriptPhysician profile
Alyson M Fish
NPI 1265622468
$3,810.03
in general payments reported to CMS, 2019-2025
27 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $941 · 2021: $764 · 2022: $465 · 2023: $483 · 2024: $249 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $679.69 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $425.25 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $410.33 | 2019-2024 | Wegovy |
| Abbvie INC. | $380.64 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.50 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $232.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $188.31 | 2020-2023 | Shingrix |
| Pfizer INC. | $185.19 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.41 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.07 | 2019-2021 | |
| Shire North American Group INC | $115.59 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $111.73 | 2021 | |
| Allergan, INC. | $108.92 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $75.77 | 2022-2023 | Quviviq |
| Upsher-Smith Laboratories LLC | $46.90 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $45.99 | 2020 | |
| Currax Pharmaceuticals LLC | $43.43 | 2021-2024 | Contrave, Onzetra Xsail |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.59 | 2025 | Caplyta |
| Corium, LLC | $33.12 | 2022-2023 | Azstarys |
| Shield Therapeutics INC | $32.94 | 2025 | |
| Novartis Pharmaceuticals Corporation | $31.30 | 2019-2020 | |
| Dexcom, INC. | $17.03 | 2023 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $15.49 | 2020 | |
| Merck Sharp & Dohme LLC | $14.91 | 2020 | |
| Adlon Therapeutics L.P. | $14.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.13 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyson Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.